Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068092 · ClinicalTrials.gov registry record · Phase 2
Olive Oil for High Risk Breast Cancer Prevention in Women
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT02068092 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 51 participants.
The verdict
NCT02068092, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a pilot study evaluating the effect of hydroxytyrosol, a component of olive oil, on mammographic density in women at high risk of developing breast cancer.
Interventions
- DRUG Hydroxytyrosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-12 |
| Est. Completion | 2021-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02068092
The ClinicalTrials.gov registry entry for NCT02068092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxytyrosol is the first listed.
NCT02068092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02068092 about?
NCT02068092 is a clinical study titled "Olive Oil for High Risk Breast Cancer Prevention in Women". This is a pilot study evaluating the effect of hydroxytyrosol, a component of olive oil, on mammographic density in women at high risk of developing breast cancer.
What is the current status of trial NCT02068092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2013-12. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02068092?
The interventions under investigation include: Hydroxytyrosol (DRUG).
Who is sponsoring clinical trial NCT02068092?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.